Patient case (clinical description): A 20-year-old man comes to the emergency due to bleeding after a tooth extraction.  The bleeding has persisted for approximately 30 minutes despite constant direct pressure.  He is a known case of Hemophilia type A treated with FVIII. Blood pressure is 95/60 mm Hg and pulse is 105/min. His weight is 70 Kg. Family history is positive for Hemophilia type A in his maternal uncle. He also has a lipoma on his left arm which he plans to remove surgically. His FVIII activity is 40%.

Patient's own account: I got my tooth extracted and I could not stop bleeding for 30 min. I'm a 20 yo dude but I have Hemophilia type A treated with FVIII. My blood pressure was 95/60 and my pulse 105/min. I'm 70 kg. My uncle on my mom's side also has type A hemophilia. I also have a fatty swelling on my left arm and I was supposed to remove it. My FVIII activity was 40%.

Clinical trial: Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies

Eligibility criteria:
Inclusion Criteria:

        Inclusion criteria for patients/caregivers in the Patient/Caregiver Study:

          -  Patients with hemophilia A (≥ 18 years of age) or caregivers of children with
             hemophilia A (≥12-<18 years of age)

          -  Group 1: Hemophilia A patients/caregivers who have switched to FVIII products with
             improved half-life for the treatment of hemophilia A during the eligibility period.
             These patients can also include those who have switched back from FVIII products with
             improved half-life to conventional FVIII replacement therapy within the Data
             Collection Period

          -  Group 2: Hemophilia A patients/caregivers who are considering switching to FVIII
             products with improved half-life within 12 months of the Start of the Documentation
             period and have been prescribed prophylaxis regimen of at least 2x/week

          -  Able to understand, read, write and speak English

          -  Provide electronic informed consent

          -  Able to access the Internet for at least 20 minutes per day during the Data Collection
             Period

        Inclusion criteria for physicians:

          -  At least 60% of time spent in direct patient care

          -  Board-certified or eligible with a Specialty in Hematology or Hematology-Oncology

          -  Physicians with a specialty in Hematology-Oncology must have at least 10% of their
             practice dedicated to treatment of hemophilia

          -  A minimum of 2 years' experience treating hemophilia A patients

        Inclusion criteria for patients in the physician chart study:

          -  Hemophilia A patients age 12 year and over

          -  Prior treatment with one of the following FVIII replacement products: Adynovate,
             Afstyla, Eloctate, or Kovaltry

          -  Patients that have 12 months of medical chart data available; 6 months on conventional
             therapy and 6 months after switching to FVIII products with improved half-life.

        Exclusion Criteria:

        Exclusion criteria for patients/caregivers in the Patient/Caregiver Study:

        - Hemophilia A patient initiated FVIII products with improved half-life for the treatment
        at time of diagnosis with hemophilia A.

        Exclusion criteria for physicians:

        - Unwilling to comply with the study protocol
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 12 Years old.


Eligibility (NLI label): Entailment